Key facts
- It has raised $340.0M across 3 recorded rounds; the latest was Early Stage VC (Series B) ($175.0M) in Mar 2024.
- Capstan Therapeutics has filed 3 Form Ds with the SEC, most recently Mar 2024 ($76.5M sold to 14 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 3 rounds
- ·Watchlist + deal alerts for Capstan Therapeutics
Create free account
No card required
Funding rounds
3 roundsMar 2024Early Stage VC (Series B)$175.0M▮
Jul 2022Early Stage VC (Series A)$102.0M▮
Nov 2021Seed Round$63.0M▮
About Capstan Therapeutics
- Industry
- Biotechnology
PA Mark — not yet priced
Capstan Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Capstan Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on Capstan Therapeutics in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.